Human medicines European public assessment report (EPAR): Bylvay, odevixibat, Date of authorisation: 16/07/2021, Revision: 12, Status: Authorised

Human medicines European public assessment report (EPAR): Latuda, lurasidone, Date of authorisation: 21/03/2014, Revision: 30, Status: Authorised

Human medicines European public assessment report (EPAR): Talmanco (previously Tadalafil Generics), tadalafil, Date of authorisation: 09/01/2017, Revision: 11, Status: Authorised

Human medicines European public assessment report (EPAR): Rivaroxaban Viatris (previously Rivaroxaban Mylan), rivaroxaban, Date of authorisation: 12/11/2021, Revision: 11, Status: Authorised

Human medicines European public assessment report (EPAR): Itovebi, inavolisib, Date of authorisation: 18/07/2025, Revision: 3, Status: Authorised

Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 4-7 May 2026

Human medicines European public assessment report (EPAR): Pregabalin Viatris (previously Pregabalin Mylan), pregabalin, Date of authorisation: 24/06/2015, Revision: 24, Status: Authorised

Human medicines European public assessment report (EPAR): Pomalidomide Viatris, pomalidomide, Date of authorisation: 16/02/2024, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Emtricitabine / Rilpivirine / Tenofovir Alafenamide Viatris, emtricitabine,rilpivirine,tenofovir alafenamide, Date of authorisation: 19/08/2025, Revision: 2, Status: Authorised

EMEA-001976-PIP02-18